ANGELA VEENSTRA: Open Payments
NPI 1811960768 · WEST DES MOINES, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$989 in 52 payments from 9 companies in 2025. Trend: 2023 $973 · 2024 $658 · 2025 $989
Food & beverage: $977Education: $12
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $194 |
| ABBVIE INC. | 11 | $176 |
| Neurocrine BioSciences, Inc. | 2 | $151 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $145 |
| Vanda Pharmaceuticals Inc. | 9 | $143 |
| Lundbeck LLC | 5 | $107 |
| Tris Pharma Inc | 2 | $32 |
| Almatica Pharma LLC | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
Products named: REXULTI, VRAYLAR, INGREZZA, CAPLYTA, FANAPT, LOREEV XR, AUSTEDO XR, Dyanavel XR.
Industry payments across IA — which companies pay providers there.
